Trastuzumab interacts with domain IV of ErbB2 and enhances its internalization, causing inhibition of the ErbB2 signalling pathway for cell proliferation, although its mode of action differs depending on cancer cell type18(Fig. 1c). This evidence concerns the gene ERBB2 and cancer.